Home
Post-approval Considerations for Changes to Manufacturing Process and Facilities - REdI 2020
U.S. Food and Drug Administration
Aug 31, 2020
12,123 views
eCTD (7/28) Generic Drugs Forum 2017
Vaccines and Related Biological Products Advisory Committee
Introduction to the Drug Master File (DMF) Review Process
CMC Considerations for CAR T Cell Product Development
Regulatory Education for Industry (REdI) Annual Conference 2024: Day 1 – Session 3
Alternatives to f2 Testing for Dissolution Similarity – f2 Bootstrapping and MSD Method
Chemistry, Manufacturing Controls (CMC) in an Investigational New Drug (IND) (7/14) REdI 2017
Electronic Common Technical Document (eCTD) and Study Data (7of15) RedI – May 29-30, 2019
Regulatory Education for Industry (REdI) Annual Conference 2024: Day 1 – Session 2
Overview of the Guidance for Industry: Control of Nitrosamine Impurities in Human Drugs
Electronic Common Technical Document (eCTD)
Regulatory Education for Industry (REdI) Annual Conference 2024: Day 2 – Session 3
How is My Medical Device Classified?
Regulatory Education for Industry (REdI) Annual Conference 2024: Day 1 – Session 1
Regulatory Education for Industry (REdI) Annual Conference 2024: Day 2 – Session 2
Regulatory Education for Industry (REdI) Annual Conference 2024: Day 2 – Session 4
Overview of the Quality System Regulation
Regulatory Education for Industry (REdI) Annual Conference 2024: Day 2 – Session 1
Advancing the Use of Complex Innovative Designs in Clinical Trials: From Pilot to Practice - Part 1
FDA Omics Days 2024: Public afternoon sessions